ENSC Ensysce Biosciences Inc
Price (delayed)
$2.29
Market cap
$3.22M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$11.45
Enterprise value
$17,340
Highlights
The company's EPS has surged by 84% YoY and by 63% QoQ
Ensysce Biosciences's debt has plunged by 65% YoY and by 22% from the previous quarter
The equity has contracted by 46% from the previous quarter
ENSC's quick ratio is down by 23% from the previous quarter
Key stats
What are the main financial stats of ENSC
Market
Valuations
Earnings
Shares outstanding
1.41M
Market cap
$3.22M
Enterprise value
$17,340
Price to earnings (P/E)
N/A
Price to book (P/B)
0.81
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$6.73M
Net income
-$7.99M
EBIT
-$6.7M
EBITDA
-$6.7M
Free cash flow
-$7.5M
Per share
Balance sheet
Liquidity
EPS
-$11.45
EPS diluted
-$11.45
Free cash flow per share
-$10.75
Book value per share
$2.84
Revenue per share
$0
TBVPS
$8.02
Total assets
$5.6M
Total liabilities
$2.22M
Debt
$301,660
Equity
$3.71M
Working capital
$3.14M
Debt to equity
0.08
Current ratio
2.42
Quick ratio
1.64
Net debt/EBITDA
0.48
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-139.8%
Return on equity
-197.5%
Return on invested capital
-639.9%
Return on capital employed
-197.5%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ENSC stock price
How has the Ensysce Biosciences stock price performed over time
Intraday
0%
1 week
-29.54%
1 month
-57.67%
1 year
-81.88%
YTD
-71.87%
QTD
-10.55%
Financial performance
How have Ensysce Biosciences's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$6.73M
Net income
-$7.99M
Gross margin
N/A
Net margin
N/A
Ensysce Biosciences's operating income has increased by 37% YoY but it has decreased by 7% QoQ
ENSC's net income is up by 25% year-on-year
Growth
What is Ensysce Biosciences's growth rate over time
Valuation
What is Ensysce Biosciences stock price valuation
P/E
N/A
P/B
0.81
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The company's EPS has surged by 84% YoY and by 63% QoQ
The price to book (P/B) is 52% lower than the last 4 quarters average of 1.7
The equity has contracted by 46% from the previous quarter
Efficiency
How efficient is Ensysce Biosciences business performance
ENSC's return on equity has surged by 75% year-on-year and by 24% since the previous quarter
The company's return on assets rose by 47% YoY and by 12% QoQ
Ensysce Biosciences's return on invested capital has increased by 21% QoQ
Dividends
What is ENSC's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ENSC.
Financial health
How did Ensysce Biosciences financials performed over time
Ensysce Biosciences's total assets is 152% higher than its total liabilities
Ensysce Biosciences's total assets has surged by 107% YoY but it has decreased by 40% QoQ
The total liabilities has contracted by 34% YoY and by 21% from the previous quarter
Ensysce Biosciences's debt is 92% less than its equity
ENSC's debt to equity has soared by 103% YoY and by 33% QoQ
Ensysce Biosciences's debt has plunged by 65% YoY and by 22% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.